A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
NCT ID: NCT04008797
Last Updated: 2025-11-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
301 participants
INTERVENTIONAL
2019-07-11
2027-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dose Escalation Part: HCC: E7386 QD Subpart + Lenvatinib
Participants with hepatocellular carcinoma (HCC) will receive E7386, once daily (QD) for 5 or 6 consecutive days followed by a period of time without treatment in Cycle 0 (6 or 7 days). Participants with HCC will receive E7386, QD in combination with lenvatinib 8 milligram (mg) (participants with body weight of less than \[\<\] 60 kilograms \[kg\]) or 12 mg (participants with body weight \>=60 kg), capsules, orally, QD in 28-day treatment cycles until PD, development of unacceptable toxicity, participant request to discontinue, withdrawal of consent, or termination of the study program.
E7386
E7386 dosing.
Lenvatinib
Lenvatinib dosing.
Dose Escalation Part: HCC: E7386 BID Subpart + Lenvatinib
Participants with HCC will receive E7386, twice daily (BID) for 5 or 6 consecutive days in Cycle 0 (6 or 7 days). Participants with HCC will receive E7386, BID in combination with lenvatinib 8 mg (participants with body weight of \< 60 kg) or 12 mg (participants with body weight \>=60 kg) capsules, orally, QD in 28-day treatment cycles until PD, development of unacceptable toxicity, participant request to discontinue, withdrawal of consent, or termination of the study program.
E7386
E7386 dosing.
Lenvatinib
Lenvatinib dosing.
Dose Escalation Part: Other ST: E7386 QD Subpart + Lenvatinib
Participants with solid tumor (ST) (except for HCC) will receive E7386, QD for 5 or 6 consecutive days followed by a period of time without treatment in Cycle 0 (6 or 7 days). Participants with ST (except for HCC) will receive E7386, QD in combination with lenvatinib 20 mg, capsules, orally, QD in 28-day treatment cycles until PD, development of unacceptable toxicity, participant request to discontinue, withdrawal of consent, or termination of the study program.
E7386
E7386 dosing.
Lenvatinib
Lenvatinib dosing.
Dose Escalation Part: Other ST: E7386 BID Subpart + Lenvatinib
Participants with ST (except for HCC) will receive E7386, BID for 5 or 6 consecutive days in Cycle 0 (6 or 7 days). Participants with ST (except for HCC) will receive E7386, BID in combination with lenvatinib 20 mg, capsules, orally, QD in 28-day treatment cycles until PD, development of unacceptable toxicity, participant request to discontinue, withdrawal of consent, or termination of the study program.
E7386
E7386 dosing.
Lenvatinib
Lenvatinib dosing.
Dose Expansion Part: HCC Subpart: Lenvatinib Only
Participants with HCC will receive lenvatinib 8 mg (participants with body weight of \<60 kg) or 12 mg (participants with body weight \>=60 kg), capsules, orally, QD in 28-day treatment cycles until PD, development of unacceptable toxicity, participant request to discontinue, withdrawal of consent, or termination of the study program
Lenvatinib
Lenvatinib dosing.
Dose Expansion Part: HCC Subpart: E7386 + Lenvatinib
Participants with HCC will receive lenvatinib 8 mg (participants with body weight of \<60 kg) or 12 mg (participants with body weight \>=60 kg), capsule, orally QD in combination with E7386 y, BID in 28-day treatment cycles until PD, development of unacceptable toxicity, participant request to discontinue, withdrawal of consent, or termination of the study program.
E7386
E7386 dosing.
Lenvatinib
Lenvatinib dosing.
Dose Expansion Part: CRC Subpart: E7386 + Lenvatinib
Participants with colorectal cancer (CRC) will receive E7386, BID in combination with lenvatinib 20 mg, capsules, orally, QD in 28-day treatment cycles until PD, development of unacceptable toxicity, participant request to discontinue, withdrawal of consent, or termination of the study program.
E7386
E7386 dosing.
Lenvatinib
Lenvatinib dosing.
Dose Expansion Part: EC Subpart: E7386 + Lenvatinib
Participants with endometrial cancer (EC) will receive E7386, BID in combination with lenvatinib 14 mg, capsules, orally, QD in 28-day treatment cycles until PD, development of unacceptable toxicity, participant request to discontinue, withdrawal of consent, or termination of the study program.
E7386
E7386 dosing.
Lenvatinib
Lenvatinib dosing.
Dose Optimization Part: EC Participants
Participants with EC will be randomized to receive 2 different doses of E7386 in combination with lenvatinib capsule or lenvatinib capsule monotherapy in 28-days cycles, or treatment of physician's choice (TPC; doxorubicin in 21-day cycles or paclitaxel in 28-day cycles \[3 weeks on/1 week off\]), until PD, development of unacceptable toxicity, participant request to discontinue, withdrawal of consent, or termination of the study program.
E7386
E7386 dosing.
Lenvatinib
Lenvatinib dosing.
Doxorubicin
Doxorubicin dosing.
Paclitaxel
Paclitaxel dosing.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
E7386
E7386 dosing.
Lenvatinib
Lenvatinib dosing.
Doxorubicin
Doxorubicin dosing.
Paclitaxel
Paclitaxel dosing.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Participants with confirmed diagnosis of unresectable HCC with any of the following criteria:
1. Histologically or cytologically confirmed diagnosis of HCC, excluding fibrolamellar, sarcomatoid or mixed cholangio-HCC tumors
2. Clinically confirmed diagnosis of HCC according to American Association for the Study of Liver Diseases (AASLD) criteria, including cirrhosis of any etiology and/or chronic hepatitis B or C infection
ST part only (except for HCC):
Participants with histologically or cytologically confirmed diagnosis of solid tumor for which no alternative standard therapy or no effective therapy exists
2. Life expectancy of \>=12 weeks
3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1
5. Adequate washout period before study drug administration:
1. Chemotherapy and radiotherapy: 3 weeks or 5 times the half-life, whichever is shorter
2. Any antitumor therapy with antibody: 4 weeks or more
3. Any investigational drug or device: 4 weeks or more
4. Blood/platelet transfusion or granulocyte colony-stimulating factor (G-CSF): 2 weeks or more Note: Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not had radiation pneumonitis
6. Adequate controlled blood pressure (BP), renal function, bone marrow function, liver function, and serum mineral level
7. At least one measurable lesion based on mRECIST (for HCC Subparts in Dose Escalation Part) or on RECIST 1.1 (for Other ST Subparts in Dose Escalation Part and all subparts in Expansion and Dose Optimization Parts) meeting following criteria
* At least 1 lesion of \>=1.0 centimeter (cm) in the longest diameter for a non-lymph node or \>=1.5 cm in the short-axis diameter for a lymph node that is serially measurable according to RECIST 1.1 using computerized tomography (CT)/magnetic resonance imaging (MRI)
* Lesions that have had external beam radiotherapy or loco-regional therapies such as radiofrequency ablation, or transarterial chemoembolisation (TACE)/ transarterial embolization (TAE) must show evidence of progressive disease based on RECIST 1.1 to be deemed a target lesion
8. For HCC participants only: Child-Pugh score A. Note: If Child-Pugh score 7 or more was observed during Screening or Baseline, the participant is ineligible and re-assessment of the Child-Pugh score is not permitted
9. For HCC participants only: Participants categorized to stage B (not amenable to locoregional therapy or refractory to locoregional therapy, and not amenable to a curative treatment), or stage C based on Barcelona Clinic Liver Cancer (BCLC) staging system
10. For HCC Subpart in Expansion Part only: prior systemic therapy for locally advanced or metastatic disease is as defined below
a. Participants who have received only one prior line of immuno oncology (IO) based regimen and have progressed on or after prior treatment with IO based regimen, or IO ineligible participants who have received no prior systemic therapy. Participants who previously received lenvatinib treatment are ineligible
11. For CRC Subpart in Expansion Part only: participants must have received at least 2 prior regimens (not exceeding 4 prior regimens) or could not tolerate standard treatment and must have received the following prior therapies in the metastatic setting if approved and locally available (progressed on at least 1 prior regimen in the metastatic setting or could not tolerate standard treatment):
Note: Adjuvant chemotherapy counts as prior systemic treatment if there is documented disease progression within 6 months of treatment completion Note: If a participant is determined to be intolerant to prior standard treatment, the participant must have received at least of 2 cycles of that therapy Note: Participants who have received oral tyrosine kinase inhibitor (example, regorafenib) are ineligible
1. Fluoropyrimidine, irinotecan and oxaliplatin with or without an anti-Vascular endothelial growth factor (VEGF) monoclonal antibody (mAb) (example, bevacizumab) Note: Capecitabine is acceptable as equivalent to fluoropyrimidine in prior treatment Note: Participants who have previously received fluoropyrimidine, oxaliplatin, and irinotecan as part of the same and only chemotherapy regimen, example, FOLFOXIRI or FOLFIRINOX, may be eligible after discussion with the Sponsor
2. Chemotherapy with anti- epidermal growth factor receptor (EGFR) mAb (cetuximab or panitumumab) for participants with rat sarcoma virus (RAS) (Kirsten rat sarcoma viral oncogene homolog \[KRAS)/ NRAS\]) wild type (WT) CRC Note: RAS (KRAS/NRAS) WT participants with right or left CRC lesions who may have not been treated with anti-EGFR mAb based on local guidelines are eligible
3. BRAF inhibitor (in combination with cetuximab ± binimetinib) for BRAF V600E mutated tumors
4. Immune checkpoint inhibitor for participants with microsatellite instability-high (MSI-H) CRC
12. For EC Subpart in Expansion Part only: Participants must have EC that has progressed after prior platinum-based chemotherapy and an anti-programmed cell death (ligand) 1 (PD-\[L\])1)-directed therapy for EC (participants ineligible for IO therapy who have progressed after prior platinum-based chemotherapy are eligible). Up to 3 prior systemic therapies, of which up to 2 for metastatic or locally advanced disease, are permitted Note: There is no restriction regarding prior hormonal therapies For Dose Optimization Part only: Participants must have EC that has progressed after prior platinum-based chemotherapy and an anti-PD-(L)1-directed therapy for EC. Up to 3 lines of prior therapy, regardless of setting, are allowed. Participants must be eligible for treatment with either single-agent paclitaxel or single-agent doxorubicin as determined by the investigator, with consideration of previous therapies received for EC. Note: Prior hormonal therapy and radiation are allowed and do not count as prior lines of therapy.
Exclusion Criteria
* Heart failure New York Heart Association (NYHA) Class II or above
* Prolongation of QT interval with Fridericias correction (QTcF) to greater than (\>) 480 millisecond (msec)
* Left ventricular ejection fraction (LVEF) less than (\<) 50 percent (%)
2. Major surgery within 21 days or minor surgery (that is, simple excision) within 7 days prior to starting study drug. Participant must have recovered from the surgery related toxicities to less than Grade 2 Note: Adequate wound healing after major surgery must be assessed clinically, independent of time elapsed for eligibility
3. Known to be human immunodeficiency virus (HIV) positive Note: the sponsor has evaluated whether to include participant with HIV. Given that this is the first combination study of E7386 with lenvatinib and that the main mechanism of action of E7386 is immunomodulation of the tumor microenvironment along with the fact that several anti-retroviral therapies have drug-drug interaction with cytochrome P450 3A (CYP3A) substrates, the sponsor has decided not to include these participants at the current time. However, further considerations will be made moving forward based on new emerging data Note: HIV testing is required at screening only when mandated by local health authority
4. Participants with proteinuria on urine dipstick testing will undergo 24-hour urine collection for quantitative assessment of proteinuria. Participants with urine protein \>=1 gram per 24 hour will be ineligible
5. Active infection requiring systemic treatment (Except for Hepatitis B and/or C \[HBV/HCV\] infection in HCC participants)
In case of HBsAg (+) participants in HCC participants:
* Antiviral therapy for HBV is not ongoing
* HBV viral load is 2000 international unit per milliliter (IU/mL) or more at the Screening Period although antiviral therapy for HBV is ongoing
* Has dual active HBV infection (HBsAg (+) and/or detectable HBV deoxyribonucleic acid \[DNA\]) and HCV infection (anti-HCV Ab (+) and detectable HCV ribonucleic acid \[RNA\]) at study entry
6. Diagnosed with meningeal carcinomatosis
7. Participants with central nervous system metastases are only eligible if they have been previously treated and are radiologically stable, (that is, without evidence of progression for at least 4 weeks prior to first dose of study treatment by repeat imaging), clinically stable, and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment
8. Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen
9. Any of bone disease/conditions as follows:
* T-score of \< minus (-) 3.0 at the left or right total hip, left or right femoral neck or lumbar spine (L1-L4) as determined by dual energy x-ray absorptiometry (DXA) scan. Participants with T-score \<-2.5 to -3.0 can only be included if treatment with a bisphosphonate (example, zoledronic acid) or denosumab has been started at least 14 days and no more than 6 months prior to the first dose of study drug
* Metabolic bone disease, such as hyperparathyroidism, Paget's disease or osteomalacia
* Symptomatic hypercalcemia requiring bisphosphonate therapy
* History of any fracture within 6 months prior to starting study drug
* Bone metastasis requiring orthopedic intervention
* Bone metastasis not being treated by bisphosphonate or denosumab. Participants may be included if treatment with bisphosphonate or denosumab has been started at least 14 days prior to the first dose of study drug. Participants with previous solitary bone lesions controlled with radiotherapy are eligible
* History of symptomatic vertebral fragility fracture or any fragility fracture of the hip, pelvis, wrist or other location (defined as any fracture without a history of trauma or because of a fall from standing height or less)
* Moderate (25% to 40% decrease in the height of any vertebrae) or severe (\>40% decrease in the height of any vertebrae) morphometric vertebral fracture at baseline
10. History of malignancy (except for original disease, or definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin, carcinoma in-situ \[example, bladder or cervix\]) within the past 24 months prior to the first dose of study drug
11. For HCC Subpart in Dose Escalation Part only: Participants who experienced discontinuation of lenvatinib, 2 or more dose reductions of lenvatinib required from initial dose level of this study due to its toxicity, or participants who experienced single dose reduction or consecutive \>=8 days dose interruption of lenvatinib within 60 days from the first dose, due to its toxicity. HCC Subpart in Expansion Part only: Participants who previously received lenvatinib treatment are ineligible.
EC Subpart in Expansion Part only: Participants previously treated with lenvatinib who experienced discontinuation of lenvatinib due to toxicity, or dose reduction to less than 10 mg of lenvatinib due to toxicity within 60 days from the first dose.
EC Dose Optimization Part only: Participants who previously received lenvatinib treatment are ineligible.
12. Bleeding or thrombotic disorders or use of anticoagulants requiring therapeutic International Normalized Ratio (INR) monitoring for HCC participants only (example, warfarin or similar agents). Treatment with low molecular weight heparin and factor X inhibitors is permitted. Treatment with antiplatelet agents is prohibited for HCC participants in Dose Escalation Part only
13. Gastrointestinal bleeding event or active hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug
14. For HCC participants only: History of hepatic encephalopathy within 6 months prior to starting study drug
15. For EC Subpart in Expansion and Dose Optimization Parts only: carcinosarcoma (malignant mixed Mullerian tumor), endometrial leiomyosarcoma, and endometrial stromal sarcomas
16. Has preexisting \>=Grade 3 gastrointestinal or non-gastrointestinal fistula
17. Evidence of current Coronavirus disease 2019 (COVID-19) infection or ongoing unrecovered active sequelae of COVID-19 infection
19. Has a known psychiatric or substance abuse disorder that would interfere with the participant ability to cooperate with the requirements of the study
20. Evidence of clinically significant disease (example, cardiac, respiratory, gastrointestinal, renal disease) that in the opinion of the investigator could affect the participant safety or interfere with the study assessments
21. Scheduled for major surgery during the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eisai Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UAMS
Little Rock, Arkansas, United States
University of California San Diego (UCSD) - Moores Cancer Center(All)
La Jolla, California, United States
Cedars-Sinai Medical Center
Los Angeles, California, United States
Pasadena Liver Center
Pasadena, California, United States
California Pacific Medical Center
San Francisco, California, United States
UCLA University of California - Los Angeles
Santa Monica, California, United States
John Muir Clinical Research
Walnut Creek, California, United States
University of Colorado Cancer Center - Anschutz Medical Campus
Aurora, Colorado, United States
Uni. Of Miami- Sylvester Cancer Centre
Miami, Florida, United States
Florida Cancer Specialists - South
Sarasota, Florida, United States
Florida Cancer Specialists - East
West Palm Beach, Florida, United States
Women's Cancer Care - Covington, LA
Covington, Louisiana, United States
University Of Mississippi Medical Center
Jackson, Mississippi, United States
Kansas City Research Institute
Kansas City, Missouri, United States
Perlmutter Cancer Center- NYU Langone Health
New York, New York, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Montefiore Medical Center (MMC) - Jack D. Weiler Hospital
The Bronx, New York, United States
MetroHealth Medical Center
Cleveland, Ohio, United States
ProMedica Flower Hospital
Sylvania, Ohio, United States
University of Oklahoma Health Science Center
Oklahoma City, Oklahoma, United States
Medical University of South Carolina
Charleston, South Carolina, United States
Sanford Cancer Centre
Sioux Falls, South Dakota, United States
Tennessee Oncology
Nashville, Tennessee, United States
Vanderbilt University Medical Center (VUMC) - Vanderbilt-Ingram Cancer Center (VICC) - Nashville
Nashville, Tennessee, United States
Mary Crowley Cancer Research
Dallas, Texas, United States
University of Texas Southwestern Medical
Dallas, Texas, United States
MD Anderson Cancer Center
Houston, Texas, United States
Fred Hutchinson/University of Washington Cancer Consortium
Seattle, Washington, United States
Sunnybrook Research Institute
Toronto, Ontario, Canada
CHUM, Unit for Innovative Therapies
Montreal, Quebec, Canada
McGill University Health Centre
Montreal, Quebec, Canada
Beijing Cancer Hospital
Beijing, , China
Peking Union Medical College Hospital
Beijing, , China
The First Bethune Hospital of Jilin University
Changchun, , China
Fujian Provincial Cancer Hospital
Fuzhou, , China
Sun Yan-sen University Cancer Center
Guangzhou, , China
Sun Yat-Sen Memrial Hospital, Sun Yat-Sen University
Guangzhou, , China
Cancer Hospital of Shandong First Medical University
Jinan, , China
Yunnan Cancer Hospital
Kunming, , China
Fudan University Cancer Center
Shanghai, , China
The Tenth People's Hospital; Shanghai Tongji University
Shanghai, , China
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
Shenzhen, , China
Tianjin Cancer Hospital
Tianjin, , China
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, , China
Odense University Hospital
Odense, , Denmark
CHU Amiens-Picardie (Hopital Sud)
Amiens, , France
CHU Bordeaux
Bordeaux, , France
CHU Cavale Blanche
Brest, , France
Centre Fran ois Baclesse
Caen, , France
Centre Jean Perrin
Clermont-Ferrand, , France
H pital Beaujon
Clichy, , France
Centre Georges-Fran ois Leclerc
Dijon, , France
Grenoble University Hospital (Centre Hospitalier Universitaire Grenoble Alpes)
La Tronche, , France
CHU de LILLE - H pital HURIEZ
Lille, , France
Hepatology, Hopital de la Croix-Rousse - 103 grande rue de la Croix-Rousse
Lyon, , France
Centre L on B rard
Lyon, , France
Institut Paoli-Calmettes
Marseille, , France
Centre Antoine Lacassagne
Nice, , France
Institut Curie - Centre de Recherche
Paris, , France
APHP Hospital Saint-Antoine
Paris, , France
AP-HP Universit de Paris, Port Royal
Paris, , France
Hopital Europeen Georges-Pompidou (HEGP)
Paris, , France
Hopital de la Croix Saint-Simon
Paris, , France
Centre Hospitalier Universitaire de Bordeaux (CHU Bordeaux)(Hopitaux de Bordeaux) - Groupe hospitalier Sud - Hopital Haut-Levequ
Pessac, , France
Centre Hospitalier Universitaire (CHU) de Poitiers
Poitiers, , France
Insitute de Canc rologie de l'Ouest - Centre Ren Gauducheau
Saint-Herblain, , France
ICANs
Strasbourg, , France
Gustave Roussy Institute (IGR)
Villejuif, , France
Clinica Oncologica AOU (Azienda Ospedaliero Universitaria) delle Marche
Ancona, , Italy
Istituto Clinico Humanitas, Rozzano
Milan, , Italy
Fondazione Policlinico Gemelli IRCCS
Rome, , Italy
Eisai#1005
Nagoya, Aichi-ken, Japan
Eisai#1011
Toyoake, Aichi-ken, Japan
Eisai#1002
Kashiwa, Chiba, Japan
Eisai#1008
Matsuyama, Ehime, Japan
Eisai#1007
Kurume, Fukuoka, Japan
Eisai#1013
Akashi, Hyōgo, Japan
Eisai#1010
Kawasaki, Kanagawa, Japan
Eisai#1012
Kamigyō-ku, Kyoto, Japan
Eisai#1003
Sayama, Osaka, Japan
Eisai#1009
Hidaka, Saitama, Japan
Eisai#1001
Chuo-ku, Tokyo, Japan
Eisai#1006
Koto-ku, Tokyo, Japan
Eisai#1015
Minato-ku, Tokyo, Japan
Eisai#1004
Chiba, , Japan
Eisai#1014
Niigata, , Japan
Korea University Guro Hospital
Guro-gu, , South Korea
National Cancer Center
Ilsandong-gu, , South Korea
Seoul National University Hospital
Jongno-gu, , South Korea
Seoul National University Hospital
Jongno-gu, , South Korea
Seoul St. Mary's Hospital
Seocho-Gu, , South Korea
Severance Hospital (Yonsei University Medical Center)
Seodaemun, , South Korea
Seoul National University Bundang Hospital
Seongnamsi Bundang, , South Korea
Samsung Medical Center
Seoul, , South Korea
Asan Medical Center
Songpa-Gu, , South Korea
University of Ulsan College of Medicine - Asan Medical Center (AMC)
Songpa-gu, , South Korea
University Hospital A Coru a
A Coruña, , Spain
Fundaci Privada Institut d Investigaci Oncol gica de Vall-Hebron (VHIO)
Barcelona, , Spain
Hospital Universitario de Ja n
Jaén, , Spain
Cl nica Universidad de Navarra
Madrid, , Spain
H. Clinico San Carlos
Madrid, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Chang Gung Medical Foundation - Kaohsiung Branch
Kaohsiung City, , Taiwan
Taichung Veterans General Hospital
Taichung, , Taiwan
National Cheng Kung University Hospital
Tainan, , Taiwan
National Taiwan University Hospital
Taipei, , Taiwan
Taipei Veterans General Hospital
Taipei, , Taiwan
Chang Gung Medical Foundation - Linkou Branch
Taoyuan District, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Mesropian A, Gris-Oliver A, Balaseviciute U, Potdar AA, Kimura T, Shen J, Torres-Marcen M, Abril-Fornaguera J, Pique-Gili M, Camell-Raventos D, Peix J, Fernandez-Martinez E, Huguet-Pradell J, Hernandez de Sande A, Keraite I, Esteban-Fabro R, Barcena-Varela M, Lindblad KE, Lujambio A, Guccione E, Thung S, Ikeda M, Kudo M, Sia D, Pinyol R, Llovet JM. E7386 enhances lenvatinib's antitumor activity in preclinical models and human hepatocellular carcinoma. Clin Cancer Res. 2025 Sep 23. doi: 10.1158/1078-0432.CCR-25-0725. Online ahead of print.
Eskander RN, Lee JY, Mirza MR, Lorusso D, MacKay H, Ray-Coquard I, Oaknin A, Gonzalez-Martin A, Hasegawa K, Corr BR, Wu X, Leary A, Hu T, Dutta L, Okpara CE, McKenzie J, Makker V. Randomized study evaluating optimal dose, efficacy, and safety of E7386 plus lenvatinib versus treatment of physician's choice in advanced/recurrent endometrial carcinoma previously treated with platinum-based chemotherapy and immune checkpoint inhibitors. Int J Gynecol Cancer. 2025 Sep;35(9):101812. doi: 10.1016/j.ijgc.2025.101812. Epub 2025 Apr 5.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-003300-32
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
2023-510275-64-00
Identifier Type: REGISTRY
Identifier Source: secondary_id
E7386-J081-102
Identifier Type: -
Identifier Source: org_study_id